Redeye initiates coverage of Medivir

We are initiating coverage of Medivir with a base case fair value of SEK 29. With an experienced management team, a deep clinical pipeline and multiple catalysts over the next 12 months, the share offers great potential for a significant rerating as the assets become de-risked.

Read more and download the research update: http://bit.ly/2Lz65V9 

Start following companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/